Phillip Williams

Oct 28, 2024 | mdpi.com | Jennifer Leigh |Sharon McGee |Lisa Vandermeer |Phillip Williams

All articles published by MDPI are made immediately available worldwide under an open access license. No special permission is required to reuse all or part of the article published by MDPI, including figures and tables. For articles published under an open access Creative Common CC BY license, any part of the article may be reused without permission provided that the original article is clearly cited. For more information, please refer to https://www.mdpi.com/openaccess.

Aug 26, 2023 | mdpi.com | Anna Wilkinson |Jean Seely |Moira Katherine Rushton |Phillip Williams

1. IntroductionApproximately one in every eight women will be diagnosed with breast cancer (BC) over their lifetime, with an estimated 28,600 new cases of BC in Canada in 2022 [1,2]. BC treatment is rapidly evolving, with ongoing advances in genomic testing, radiation therapy, surgery and systemic therapy. BC molecular subtype, based on hormone receptor (HR) and HER2/neu (HER2) status, is increasingly driving specialised therapy choices and informing improved subtype-specific survival [3].